Perturbation type | Gene | Citation | Cancer type | Gene-disease relation |
---|---|---|---|---|
Top gains | GRAMD2B GRAMD3) (Isoform switch) | 20502531: 17699851 | KIRC | Differentially expressed in KIRC patients compared to expression profiles in heathy controls |
Top gains | GRAMD1C (Isoform switch) | 14641932 | KIRC | Differentially expressed in KIRC patients compared to expression profiles in heathy controls |
Top losses | VSIG8 (Isoform switch) | 21253009 | KIRC | Differentially expressed in KIRP patients compared to expression profiles in noncancerous kidney cortical samples |
Top losses | SHC1 (Isoform switch) | 27993167 | KIRC | Highly expressed in better outcome KIRC cases |
Top cancer-specific gains | CDC25C | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific gains | CDC45 | 20502531 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific gains | CDKN2A | 23792563 | KIRC | Deletion associated with KIRC. |
Top cancer-specific gains | EME1 | 20502531 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific gains | CENPA | 28553932 | KIRC | Differentially expressed in tumor samples in mouse model. |
Top cancer-specific gains | FASLG | 20572163 | RCC | Polymorphism associated with risk of RCC. |
Top cancer-specific gains | KIF14 | 14641932:19123481 | KIRC:KIRP | Differentially expressed in tumor samples in KIRC and KIRP. |
Top cancer-specific gains | LGALS9C | 25716202 | KIRC | Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. |
Top cancer-specific gains | MCM10 | 26859141 | KIRC | Down-regulated in KIRC and target for miR-146a-5p. |
Top cancer-specific gains | NEIL3 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific gains | SGO1 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific gains | MLC1 | 27633759 | KIRC | The activation of RhoA/ROCK/MLC signaling by honokiol suppresses the migration of highly metastatic RCC. |
Top losses | ASB14 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | BIK | 16322756 | KIRC | The conditional restoration of Nbk/Bik expression led to apoptotic death of RCC but not of nonmalignant renal epithelia. |
Top losses | BNIPL | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | CLNK | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | ESRRB | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | FBN3 | 26807193 | CRCC | Mutation in FBN3 associated with CRCC. |
Top losses | FOXA3 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | GRIK2 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | HAP1 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | OLFM4 | 24649153 | RCC | OLFM4 was not detected in the 86 RCC cases. OLFM4 is likely to have tumor suppressive properties in RCC. |
Top losses | RAB40A | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | SOX30 | 28029648 | KIRP | Overexpressed in KIRP black vs. white KIRP patients with a fold change ≥ 2. |
Top losses | TCAP | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top losses | USP44 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
Top cancer-specific losses | BIK | 16322756 | KIRC | The conditional restoration of Nbk/Bik expression led to apoptotic death of RCC but not of nonmalignant renal epithelia. |
SMGs within edgetic gains or losses | ELOC | 27530247 | KIRC | ELOC missense mutations associated with KIRC. |
SMGs within edgetic gains or losses | HIF1A | 15350301 | KIRC | HIF1A polymorphism associated with KIRC. |
SMGs within edgetic gains or losses | KAT7 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
SMGs within edgetic gains or losses | MAGI1 | 14641932 | KIRC | Differentially expressed in tumor samples compared to normal samples. |
SMGs within edgetic gains or losses | PIK3CA | 26233890 | KIRC | The PI3K/AKT pathway is modestly mutated but highly activated in RCC; representing a promising drug target. |
SMGs within edgetic gains or losses | RNF2 | 28827316 | KIRC | RNF20 was demonstrated to have tumor suppressor activity in KIRC. |
SMGs within edgetic gains or losses | TP53 | 28551630 | KIRC | Immunoreactivity for TP53 was elevated in cancer cells when compared to unchanged kidney; |
SMGs within edgetic gains or losses | VHL | 27530247 | KIRC | VHL missense mutations associated with KIRC. |
To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button